Sandra A. Gardiner serves as Chief Financial Officer, Executive Vice President - Finance, Treasurer, Secretary of the Company. Ms. Gardiner served as Executive Vice President and Chief Financial Officer of Cutera, Inc., a global provider of laser, light, and other energy-based aesthetic systems, from July 2017 to November 2019. Previously, Ms. Gardiner served as Vice President, Finance and Chief Financial Officer of Tria Beauty, Inc., a medical device manufacturer of laser based aesthetic devices, from April 2015 until it was acquired in April 2017. Ms. Gardiner has also been Chief Financial Officer of Aptus Endosystems, Inc., Ventus Medical, Inc., Vermillion, Inc. and Lipid Sciences, Inc. Earlier in her career, Ms. Gardiner served in roles of increasing responsibility at Cardima, Inc., Comac, Inc. and Advanced Cardiovascular Systems, Inc. Ms. Gardiner holds a Bachelor of Arts degree in Management Economics from the University of California, Davis.
As the Chief Financial Officer, Executive Vice President - Finance, Treasurer и Secretary of Pulse Biosciences Inc, the total compensation of Sandra Gardiner at Pulse Biosciences Inc is $2,097,570. There are no executives at Pulse Biosciences Inc getting paid more.
Sandra Gardiner is 54, she's been the Chief Financial Officer, Executive Vice President - Finance, Treasurer и Secretary of Pulse Biosciences Inc since 2019. There are 8 older and 2 younger executives at Pulse Biosciences Inc. The oldest executive at Pulse Biosciences Inc is Robert Duggan, 75, who is the Independent Chairman of the Board.
Sandra's mailing address filed with the SEC is C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD, CA, 94545.
Over the last 8 years, insiders at Pulse Biosciences Inc have traded over $0 worth of Pulse Biosciences Inc stock and bought 18,070,761 units worth $194,618,110 . The most active insiders traders include Robert W Duggan, Mahkam Zanganeh и Manmeet Singh Soni. On average, Pulse Biosciences Inc executives and independent directors trade stock every 52 days with the average trade being worth of $6,179,107. The most recent stock trade was executed by Burke Thomas Barrett on 20 May 2024, trading 10,000 units of PLSE stock currently worth $85,600.
pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and
Pulse Biosciences Inc executives and other stock owners filed with the SEC include: